Validation of a testosterone and dihydrotestosterone liquid chromatography tandem mass spectrometry assay: Interference and comparison with established methods.
Wang C, Shiraishi S, Leung A, Baravarian S, Hull L, Goh V, Lee PW, Swerdloff RS
Purpose
Conclusion
Studies (2)
Purpose
Summary of Findings
Biospecimens
FluidSerumPreservation Types
FrozenDiagnoses
NormalOther diagnosesPlatforms
SteroidLC-MS or LC-MS/MSSteroidRadioimmunoassayPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Preaquisition Diagnosis/ patient condition Hypogonadal maleNormal malePreaquisition Other drugs NoneOral TTransdermal T and DHTAnalyte Extraction and Purification Analyte purification Celite chromatographyNoneRadioimmunoassay Specific Technology platform LC-MS/MS
Purpose
The purpose of this study was to determine the effects of collection tube type, anticoagulant, fluoride and T esters on the quantification of T and DHT by LC-MS/MS. Serum specimens were frozen at -20 degrees C and thawed once prior to this analysis.
Summary of Findings
Anticoagulant had no effect on serum T or DHT levels, but when serum T was monitored at m/z 289.3/97.1, serum collected in tubes containing clot activator had 4-fold higher concentrations of T than serum collected in plain tubes. Treatment with hydrochloric acid, modifying the column, and monitoring at m/z 289.2/109.0 eliminated this interference. Collection of serum in tubes containing fluoride resulted in lower T and DHT levels than in serum collected in plain tubes. When serum was collected in the presence of TE, but not TU, there was a dose dependent increase in measured T that could be prevented by the addition of fluoride.
Biospecimens
FluidSerumFluidBloodPreservation Types
FrozenDiagnoses
NormalPlatforms
SteroidLC-MS or LC-MS/MSPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Biospecimen Acquisition Anticoagulant CitrateEDTAHeparinNoneBiospecimen Acquisition Type of collection container/solution Fluoride tubePlain tubeTube containing testosterone enanthateTube with clot activator and gelLC-MS or LC-MS/MS Specific Detection method Monitoring at m/z 289.2/109.0Monitoring at m/z 289.3/97.1